Skip to content

Advertisement

Radiation Oncology

What do you think about BMC? Take part in

Open Access

Erratum: Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options

  • Antonio José Conde Moreno1Email author,
  • Carlos Ferrer Albiach1,
  • Rodrigo Muelas Soria1,
  • Verónica González Vidal1,
  • Raquel García Gómez1 and
  • María Albert Antequera1
Radiation Oncology201510:154

https://doi.org/10.1186/s13014-015-0444-2

Received: 23 March 2015

Accepted: 23 March 2015

Published: 28 July 2015

The original article was published in Radiation Oncology 2014 9:258

Erratum

After the publication of this work [1], we noticed that an incorrect version of Table two (Table 1 here) [1] was published. The correct version of Table two (Table 1 here) is provided here.
Table 1

Current Ongoing trials for Prostate Cancer Oligometastases in 2014 (www.clinicaltrials.gov)

Study

ClinicalTrials.gov Identifier

Phase

Aim

Arms

Primary Objetives

Secondary Objetives

Radiotherapy for Oligometastatic Prostate Cancer

NCT01859221

2

Efficacy and safety in patients with prymary active or not

2: CR and HN

Improvement in median progression-free survival in patients with metastatic prostate cancer over historic control rates in hormone receptive and castration resistant subgroups.

Improvement in overall survival of patients with metastatic prostate cancer.

University of Florida

     

Treatment failure rates in patients treated with stereotactic radiation for metastatic prostate cancer. after type of secondary outcome.

      

Quality of life in patients treated with stereotactic radiation for metastatic prostate cancer.

Stereotactic Radiosurgery in Treating Patients With Metastatic Breast Cancer, Non-Small Cell Lung Cancer, or Prostate Cancer

NCT02206334

1

Safety Study

1

To determine the recommended SBRT dose for each of the metastatic locations being treated given the individual and overlapping fields when multiple metastases are treated with SBRT in a national clinical trials network setting.

I. To estimate rates of > = grade 3 (CTCAE 4.0) adverse events other than a dose-limiting toxicity which is possibly, probably, or definitely related to treatment and which occurs within 6 months from the start of SBRT to multiple metastases.

NRG Oncology Foundation, Inc.

     

II. To estimate the rates of long-term adverse events occurring up to 2 years from the end of SBRT.

Collaborator: NCI RTOG

     

III. To explore the most appropriate and clinically relevant technological parameters to ensure quality and effectiveness throughout radiation therapy processes, including imaging, simulation, patient immobilization, target and critical structure definition, treatment planning, image guidance and delivery.

Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer

NCT01558427

2

Defer the start of ADT

2: A. Active surveillance

Androgen deprivation therapy free survival.

Quality of life

University Hospital, Ghent

   

B. Surgical or radiotherapy treatment of metastases

  

Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer

NCT02192788

2

Safety and Efficacy Study

1

Local and symptomatic control of oligometastases treated by SBRT

Biochemical progression rates

GICOR

     

Progression-free survival,

Collaborators:

     

Chemotherapy-free survival and overall survival.

SBRT-SG

     

Analyze toxicities and quality of life of patients before and after treatment

SEOR

      

Consorcio Hospitalario Provincial de Castellón

      

CR Castrate resistant, HR Hormone Receptive, NCI National Cancer Institut, RTOG Radiation Therapy Oncology Group, ADT androgen deprivation therapy

CTCAE 4.0: Common Terminology Criteria for Adverse Events SBRT-SG: Sterotactic Body Radiation Therapy Spanish Group

GICOR: Spanish Group of clinical Investigation in Radiation Oncology SEOR: Spanish society of Radiation Oncology

Notes

Authors’ Affiliations

(1)
Servicio de Oncología Radioterápica, Instituto Oncológico de Castellón “Dr. Altava”, Consorcio Hospitalario Provincial de Castellón

Reference

  1. Conde Moreno AJ et al. Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options. Radiation Oncology. 2014;9:258.PubMedView ArticleGoogle Scholar

Copyright

© Moreno et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement